Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06821087 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19
A Phase 2 study, sponsored by University of Texas at Austin.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT06821087 is a Phase 2 study that has completed, run by University of Texas at Austin. The registered enrollment target is 20 participants.
The verdict
NCT06821087, a Phase 2 study, has completed, sponsored by University of Texas at Austin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
Plain Language Summary: This study is a clinical trial to see if ketamine can help treat symptoms of Long COVID, especially fatigue and problems with thinking clearly (often called "brain fog"). Long COVID is a condition that affects people even after they have recovered from COVID-19, causing ongoing health issues like tiredness, memory problems, and difficulty concentrating. Right now, there are very few treatments available for these symptoms, and many people are looking for new options to feel better. What is the study trying to find out? Does ketamine help reduce fatigue and improve thinking skills in people with Long COVID? Does ketamine improve overall quality of life and mental health for people with Long COVID? Is ketamine safe and well-tolerated for people with Long COVID? How does ketamine affect the body's biological processes, like inflammation and brain function? How will the study work? The study will include 20 adults between 18 and 65 years old who have Long COVID symptoms like fatigue or brain fog. Participants will first meet with researchers to answer health questions, take surveys about their symptoms, and do tests to check their thinking skills. All participants will also have a brain scan (MRI) and give a blood sample to look at markers of inflammation. Participants will then receive four ketamine treatments over two weeks at a specialized clinic. The ketamine will be given as an injection, with the dose slightly increasing during the treatment period. After six weeks, participants will return for follow-up tests to see if their symptoms have improved. This includes repeating the surveys, thinking tests, MRI and blood test. Why ketamine? Ketamine is a medicine originally used for anesthesia but has also been found to help with depression and other mental health issues. Researchers think it might help with Long COVID symptoms because it can reduce inflammation in the brain and improve how the brain functions. People with Long COVID often
Interventions
- DRUG Ketamine only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2026-06-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06821087
The ClinicalTrials.gov registry entry for NCT06821087 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas at Austin, which has 257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ketamine only is the first listed.
NCT06821087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06821087 about?
NCT06821087 is a clinical study titled "Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19". Plain Language Summary: This study is a clinical trial to see if ketamine can help treat symptoms of Long COVID, especially fatigue and problems with thinking clearly (often called "brain fog"). Long COVID is a condition that affects people even after they have recovered from COVID-19, causing ongo...
What is the current status of trial NCT06821087?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-04-28. Estimated completion is 2026-06-22.
What interventions are being tested in trial NCT06821087?
The interventions under investigation include: Ketamine only (DRUG).
Who is sponsoring clinical trial NCT06821087?
This trial is sponsored by University of Texas at Austin, which has 257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.